Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 577-583

  Luo, Jie ^a   Chen, Ming ^a   Huang, Hengliu ^a   Yuan, Tao ^a   Zhang, Mingxu ^a   Zhang, Kejun ^a   Deng, Shaoli ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alphafetoprotein; Circulating miRNA; Hepatocellular carcinoma; MiRNA 122a; MiRNA 221; Molecular diagnostics

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA 122; MICRORNA 221; PROTEIN MICRORNA 122A; SMALL NUCLEAR RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CLASSIFIER; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RNA ISOLATION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; VOLUNTEER;

EID: 84878557630     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S44215     Document Type: Article

References (41)

1. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents. Lyon, France: International Agency for Research in Cancer Scientific Publications; 2007. Available from: http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/CI5vol9-A.pdf. Accessed April 28, 2013.
2. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4: 424-432.
3. Calin GA, Croce MC. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-866.
4. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838.
5. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47:1955-1963.
6. Ambros V. The functions of animal microRNAs. Nature. 2004;431: 350-355.
7. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269.
8. Fu X, Wang Q, Chen J, et al. Clinical significance of miRNA-221 and its inverse correlation with p27(Kip1) in hepatocellular carcinoma. Mol Biol Rep. 2011;38:3029-3035.
9. Gramantieri L, Fornari F, Ferracin M, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 2009;15:5073-5081.
10. Galardi S, Mercatelli N, Giorda E, et al. miRNA-221 and miRNA-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27 Kip1. J Biol Chem. 2007;282: 23716-23724.
11. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/ p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27:5651-5661.
12. Tannapfel A, Grund D, Katalinic A, et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer. 2000;89:350-355.
13. Nakai S, Masaki T, Shiratori Y, et al. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol. 2002;20:769-775.
14. Kutay H, Bai S, Datta J, et al. Downregulation of miRNA-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem. 2006;99:671-678.
15. Chang J, Nicolas E, Marks D, et al. miRNA-122, a mammalian liverspecific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1:106-113.
16. Fornari F, Gramantieri L, Giovannini C, et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2009;69: 5761-5767.
17. Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2008;49:1571-1582.
18. Bai S, Nasser MW, Wang B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to Sorafenib. J Biol Chem. 2009;284:32015-32027.
19. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
20. American Cancer Society (ACS). Liver Cancer. 2012. Accessed at http://www.cancer.org/acs/groups/cid/documents/webcontent/003114-pdf.pdf on January 18, 2013.
21. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60;167-179.
22. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ 3rd, Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol. 2008;21:1139-1146.
23. Taylor DD, Taylor CG. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13-21.
24. Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47: 784-791.
25. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065-7070.
26. Yanaihara N, Caplen N, Bowman E, et al. Unique micro-RNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189-198.
27. Rong M, Chen G, Dang Y. Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer. 2013;13:21.
28. Yang QE, Racicot KE, Kaucher AV, Oatley MJ, Oatley JM. MicroRNAs 221 and 222 regulate the undifferentiated state in mammalian male germ cells. Development. 2013;140:280-290.
29. Xu J, Wu C, Che X, et al. Circulating microRNAs, miRNA-21, miRNA-122, and miRNA-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog. 2011;50:136-142.
30. Porta C, De Amici M, Quaglini S, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2008;19: 353-358.
31. Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010;59: 1687-1693.
32. Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13:817-826.
33. Giannelli G, Marinosci F, Trerotoli P, et al. SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. Int J Cancer. 2005;117: 506-509.
34. Giannelli G, Fransvea E, Trerotoli P, et al. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta. 2007;383:147-152.
35. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis c virus infection. Science. 2010;327:198-201.
36. Kaplan DE, Reddy KR. Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Clin Liver Dis. 2003;7:683-714.
37. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35:S72-S78.
38. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003;139:128.
39. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G. Hepatitis C-related carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003;98:2060-2063.
40. Qiu LP, Fan HX, Jin WS, et al. MiR-122-induced downregulation of HO-1 negatively affects miRNA-122-mediated suppression of HBV. Biochem Biophys Res Commun. 2010;398:771-777.
41. Fan G, Wang CM, Tian C, et al. MiR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncol Rep. 2011;26:1281-1286.